Picture of Medacta SA logo

MOVE — Medacta SA News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

Switzerland's Medacta H1 revenue rises 9.7% in constant currency

Switzerland's Medacta H1 revenue rises 9.7% in constant currency


Overview

  • Swiss medical device maker's preliminary H1 revenue rose 9.7% in constant currency

  • Growth driven by innovations, new surgeon recruitment, and expanded medical education

  • Company confirmed FY 2026 and mid-term outlook


Outlook

  • Medacta targets 2026 revenue growth of 10% to 14% in constant currency

  • Company expects 2026 adjusted EBITDA margin to expand by around 50bps vs prior year (27.9%)

  • Medacta sees mid-term (2024–2027E) revenue CAGR of 12% to 15% in constant currency


Result Drivers

  • INNOVATION AND NEW PRODUCTS - Growth attributed to differentiating innovations, including the AMIS platform for Hip, NextAR AR navigation systems, and new products in Knee and Extremities

  • NEW SURGEON RECRUITMENT - Increased volumes from new surgeons attracted through expanded sales force and medical education initiatives

  • US SALES CHANNEL TRANSITION - Slower US growth in Spine due to ongoing transition to direct sales and Medacta-focused agents, with partial offset from new customer revenues


Company press release: ID:nEQ4xzN24a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

EUR 368 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Medacta Group SA is CHF170.50, about 25.9% above its July 30 closing price of CHF135.40

  • The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 30 three months ago


Reuters Recommended Reads

  • July 30 - Stryker beats quarterly estimates on strong demand for medical devices

  • July 29 - GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength

  • July 29 - Bausch + Lomb Q2 revenue beats on surgical segment growth; lifts outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Medacta SA

See all news